The molecular mechanisms underlying the caudal-to-rostral progression of Lewy body pathology in 26
4 organization of transcriptomic changes in physiological and pathological conditions may aid in 66 understanding these changes on a functional level during disease progression in PD. 67 In the present study, we aim to unravel the molecular factors underlying selective vulnerability to LB 68 pathology during PD progression. We used transcriptomic postmortem human brain data of non-69 neurological adult donors from the AHBA and analyzed brain regions involved in Braak LB stages 18 . We 70 identified genes whose expression patterns increase or decrease across these regions, referred to as 71
Braak stage-related genes (BRGs) and hypothesized that they might contribute to higher vulnerability to 72
LBs in PD brains based on the sequence of events as postulated by Braak et al. 1 (Figure 1 ). We validated 73 the relevance of the identified BRGs to PD progression with two datasets of non-neurological controls 74 (Genotype-Tissue Expression project (GTEx) 19 and UK Brain Expression Consortium (UKBEC) 20 ) and two 75 datasets of PD donors. We found altered expression patterns in patients with PD and incidental Lewy 76 body disease (iLBD), who are assumed to represent the pre-clinical stage of PD 11, 21 6 BRGs present in UKBEC, 139 out of 317 (43.8%) negatively correlated BRGs and 400 out of 571 (70.1%) 119 positively correlated BRGs were differentially expressed between R1 and R6 (|FC R1-R6 | > 1, BH-corrected 120 P < 0.05, and Figure 2d ). Second, we used RNA-sequencing (RNA-seq) data from 88-129 individuals in 121 the GTEx consortium 19 and selected samples of the substantia nigra (R3), amygdala (R4), anterior 122 cingulate cortex (R5), and frontal cortex (R6). For the 883 BRGs present in the GTEx consortium, 204 out 123 of 318 (64.2%) negatively correlated BRGs and 475 out of 565 (84.1%) positively correlated BRGs were 124 differentially expressed between R3 and R6 in this dataset (FC R3-R6 | > 1, BH-corrected P < 0.05, and 125 Figure 2e ). Together, this indicates that the expression patterns of BRGs in the brain are consistent 126 across non-neurological individuals. 127 We next hypothesized that if the identified BRGs are associated with vulnerability to PD, they are also 128 indicative of vulnerability differences between PD patients and age-matched controls. To test this 129 7 R4-R6 also have higher expression in controls compared to PD patients. These findings thus support the 147 relation of BRGs with PD vulnerability encountered in brain regions of non-neurological individuals and 148
show how their expression may influence the vulnerability at a region-specific level as well as between 149 patients and controls. 150
Braak stage-related co-expression modules 151
In addition to the expression of individual genes, we analyzed non-neurological brains from the AHBA to 152 examine the expression of gene sets that may jointly affect the vulnerability of brain regions to PD. To 153 study genetic coherence in vulnerable brain regions, we clustered all 20,017 genes into modules based 154 on their pairwise co-expression across regions R1-R6. The module eigengene, which summarizes the 155 overall expression of genes within a module, was correlated with the labels of regions as defined by 156
Braak stages (Figure 3a and Supplementary Table 9 ). Whether or not the modules showed expression 157 patterns that correlated with Braak stages, their expression in the arcuate nucleus of medulla, locus 158 coeruleus and CA2-field was consistently low (Figure 3b and Supplementary Figure 5 ). For the CA2-field 159 this might be explained by the presence of Lewy neurites rather than LBs 18 . Correlations with Braak 160 stages were mostly driven by the expression change between regions involved in preclinical stages (R1-161 R3) and clinical stages (R4-R6), which were most evidently reflected in R3 or R4. In addition, regions R1-162 R3 showed more extreme expression values (high and low) than in regions R4-R6. 163
We selected 23 co-expression modules for which the eigengene was significantly correlated with Braak 164 stages (P < 0.0001, BH-corrected). Module M39 showed the lowest correlation with Braak stages (r = -165 0.87 and BH-corrected P = 3.65e-7), while M50 showed the highest correlation (r = 0.92 and BH-166 corrected P = 4.42e-7). Most modules were significantly enriched for BRGs that were similarly correlated 167 with Braak stages (Figure 3c ). For functional characterization, modules were further assessed for 168 enrichment of cell-type markers 23 , and gene sets associated with functional GO-terms or diseases. 169
We found that modules that were negatively correlated with Braak stages were enriched for markers for 170 all different cell-types, and linked to various functions and diseases. M39 was enriched for markers of 171 astrocytes and endothelial cells, and the function membrane raft which plays a role in neurotransmitter as locomotory behavior and dopamine biosynthetic process, as well as diseases including 174 dopa−responsive dystonia, dystonialimb, and tremor, highlighting their role in motor circuitry. M47 was 175 enriched for endothelial cell markers and genes involved in immune response, blood coagulation, 176 interferon-gamma-mediated signaling pathway, and oxygen transport. This module was also enriched for 177 genes involved in auto-inflammatory or auto-immunity disorders, e.g. hypersensitivity, infection, and 178 inflammation. These modules and their associated pathways were associated with the preclinical stages 179 of PD, because of their higher expression in regions R1-R3. 180
Modules that were positively correlated with Braak stages were specifically enriched for neuronal markers 181 and related functions (e.g. axon, cell junction, and chemical synaptic transmission) reflecting higher 182 expression of these modules in the synapse-dense cerebral cortex. Furthermore, M157 was enriched for 183 the function olfactory bulb development, M105 for functions such as cell junction, postsynaptic density, 184 calcium ion binding, and genes linked to bipolar disorder, M153 for functions cell junction and 185 postsynaptic membrane, and both M153 and M50 were linked to tobacco use disorder. Overall, gene co-186 expression across Braak stage-related regions R1-R6 revealed interesting modules that highlight 187 pathways and potential gene interactions involved in preclinical and clinical stages of PD. 188
Variable expression of BRGs is not fully explained by variations in cellular
189 composition 190 We validated whether the identification of BRGs was confounded by variations in cellular compositions 191 across the six Braak stage-related regions R1-R6. We applied population-specific expression analysis 192 (PSEA) 24 to the AHBA to validate the cell-type specificity of each of the 960 BRGs. We found all 960 193
BRGs to be differentially expressed (BH-corrected P < 0.05 and β ≠ 0) between regions R1 and R6 after 194 correcting for five major cell-types (neurons, astrocytes, oligodendrocytes, microglia, and endothelial 195 cells). For example, the neuronal marker ADCY1 which was identified as a BRG remains differentially 196 expressed between regions R1 and R6 when corrected for neurons or other cell-types ( Figure 4 ). 197
Similarly as for BRGs, PSEA analysis on all 23 Braak stage related co-expression modules showed 198 significant differential expression between regions R1 and R6 which cannot be fully explained by 199 differences in cellular composition. 200
In the PD datasets, not all BRGs were found significant after correction for cellular composition, however 201 smaller changes can be expected when comparing regions that are less distant (R1-R3 and R3-R4/R5). 202 Similar to the differential expression analysis without correction for cellular composition (Supplementary 203 Figure 3 ), PSEA revealed most changes between brain regions than between patients and controls 204 (Supplementary Figure 6) . 205 206 Braak staging 207 We found that the expression patterns of several PD-implicated genes, identified in the two most recent 208 PD genome-wide association studies 7, 8 , were correlated with the Braak LB staging scheme. These 209 included BRGs (SCARB2, ELOVL7, SH3GL2, SNCA, BAP1, and ZNF184; Table 1 and Supplementary 210 LB pathology. We further validated this concept in two cohorts of PD patients in which SNCA expression 218 similarly increased across the medulla oblongata (R1), locus ceruleus (R2), and substantia nigra (R3) of 219 PD-, iLBD patients, and age-matched controls. SNCA was significantly lower expressed in region R1 220 compared to R2 and R3 in PD-and iLBD patients, but not in controls ( Figure 5f ). In the RNA-seq dataset, 221
Expression of several Parkinson's disease-implicated genes are related to
SNCA was significantly lower expressed in the substantia nigra (R3) compared to the medial temporal 222 gyrus (R4/R5) in PD patients, but again not in controls ( Figure 5g ). Altogether, SNCA expression patterns 223 could be replicated in brain regions of age-matched controls, however changes were larger between brain 224 regions in PD-and iLBD cases. We further assessed SNCA expression using PSEA in the AHBA ( Figure  225 5h) and found that changes were independent of neuronal or other cell-type densities when comparing 226 different brain regions. In PD datasets results were scattered and did not align between both PD 227 microarray and RNAseq datasets because of the small sample sizes and the comparison of different 228 brain regions ( Supplementary Figure 8) . 229
Co-expression analysis in non-neurological brains from the AHBA revealed several dopaminergic genes 230 present in module M127. Their expression patterns were further investigated together with SNCA which is 231 also known to regulate dopamine homeostasis 25 . GCH1, TH, and SLC6A3 (DAT) are related to the 232 functional term dopamine biosynthetic process, and SLC18A2 (VMAT2) is known to store dopamine into 233 synaptic vesicles 26 . Unlike SNCA, the expression of GCH1, TH, SLC6A3, and SLC18A2 was higher 234 expressed in regions involved at preclinical stages than those involved at clinical stages. Furthermore, all 235 these dopaminergic genes and SNCA showed a clear peak of expression in region R3 which includes the 236 substantia nigra, basal nucleus of Meynert, and CA2-field ( Figure 6 and Supplementary Figure 9 ). 237
Discussion

238
In PD, the progressive accumulation of LB pathology across the brain follows a characteristic pattern, 239 which starts in the brainstem and subsequently evolves to more rostral sites of the brain (Braak 240 ascending scheme) 1 . Using transcriptomic data of non-neurological brains, we identified genes (e.g. 241 SNCA, SCARB2, and ZNF184) and modules of co-expressed genes for which the expression decreased 242 or increased across brain regions defined by the Braak ascending scheme. Interestingly, these patterns 243 were disrupted in brains of patients with PD across regions that are preclinically involved in the 244 pathophysiology of PD. One gene co-expression module that showed higher expression in preclinically 245 involved regions was related to dopamine synthesis, locomotory behavior, and microglial and neuronal 246 activity. Another module was related to blood oxygen transport, the immune system, and may involve 247 endothelial cells. Our results highlight the complex genetic architecture of PD in which the combined 248 effects of genetic variants and co-expressed genes may underlie the selective regional vulnerability of the 249 brain. 250
Multiple studies suggests that a cytotoxic role and prion-like transfer of α-synuclein may contribute to its 251 progressive spread across the brain in PD, assuming a gain-of-function 3, 27, 28 . In line with this assumption 252 are reports of familial PD caused by SNCA multiplications, suggesting a SCNA dosage effect in causing 253 PD 5, 29 . Interestingly, in contrast to the temporal and spatial pattern of the α-synuclein distribution 254 associated with the ascending Braak scheme in PD, the SNCA expression signature across brain regions 255 R1-R6 in non-neurological brains followed a reverse pattern with lowest expression in preclinically 256 involved regions (brainstem) and highest expression in clinically involved regions ( suppressor. Cancer-associated mutations within this gene were found to destabilize protein structure 282 promoting β-amyloid aggregation in vitro, which is the pathological hallmark in Alzheimer's disease 33 . 283
A number of functional pathways have been suggested to play a role in the pathogenesis of PD, such as 284 lysosomal function, immune system response, and neuroinflammation [6] [7] [8] 34 . We identified modules of 285 genes that co-express across the six Braak stage-related regions and found they were enriched for genes 286 related to molecular processes that have been linked to the (pre)clinical symptoms and functional deficits 287 in PD. 288
One negatively correlated module M127 was enriched for genes related to functions and diseases 289 involving dopamine synthesis and motor functions. This module also contains the PD variant-associated 290 gene GCH1 (GTP cyclohydrolase 1) that is known to co-express with TH (tyrosine hydroxylase, the 291 enzyme responsible for converting tyrosine to L-3,4-dihydroxyphenylalanine (L-DOPA) in the dopamine 292 synthesis pathway) to enhance dopamine production and enable recovery of motor function in rat models 293 of PD 35 . In this study, both GCH1 and TH occur in M127 and thus were co-expressed across brain 294 regions involved in Braak stages supporting their interaction ( Figure 6 and Supplementary Figure 9 ). The 295 higher expression in the more vulnerable brain regions R1-R3 indicates that GCH1, TH, and possibly 296 other genes within module M127 are essential to maintain dopamine synthesis that is affected in the early 297
Braak stages of PD. Indeed, by inhibiting TH activity, α-synuclein can act as a negative regulator of 298 dopamine release 26, 36 . In this module, SLC18A2 (VMAT2; vesicular monoamine transporter 2) and 299 SLC6A3 (DAT; dopamine transporter) were also present, which are important for storage of dopamine 300 and transport in the cell 26 . Interestingly, dopamine may increase neuronal vulnerability, as was suggested 301 by an earlier study showing that α-synuclein is selectively toxic in dopaminergic neurons, and 302 neuroprotective in non-dopaminergic cortical neurons 37 . Cell-type marker enrichment showed that module 303 M127 was enriched for microglia-and neuronal markers, suggesting a role in neuroinflammation. α-304
Synuclein aggregates evoke microglia activation which in turn promotes aggregated protein propagation 305 to other brain regions, possibly even from the gut or periphery to the brain 27,34 . The higher expression of 306 microglial genes within module M127 may contribute to the higher vulnerability of brain regions affected 307 during preclinical stages to form protein aggregates. Further investigation of genes within module M127 will provide a better understanding of the molecular mechanisms underlying microglia activation, 309 dopaminergic pathways and motor functions. 310
Another negatively correlated module M47 was enriched for endothelial cell markers and genes involved 311 in functions and disorders that relate to the immune response and oxygen transport in blood. One 312 previous case-control study showed that anemia or low hemoglobin levels may precede the onset of 313 PD 38 . Several studies using blood transcriptomic meta-analysis revealed genes associated with 314 hemoglobin and iron metabolism were downregulated in PD patients compared to controls [39] [40] [41] . In our 315 study, several hemoglobin genes (HBD, HBB, HBA1, HBA2, and OASL) were also present in module 316 M47 of which HBD and HBB have been described to be highly interconnected with SNCA 41 . We also 317 found an association between the interferon-gamma-mediated signaling pathway and M47 in which OASL 318 also plays a role. Module M47 was negatively co-expressed with SNCA. Notably, a significant loss of 319 negative co-expression between SNCA and interferon-gamma genes in the substantia nigra has been 320 demonstrated in PD patients as compared to controls 42 . This loss may result from a downregulation of 321 genes within M47 in the substantia nigra of PD patients, similarly as was observed in PD blood 322 transcriptomics [39] [40] [41] . Therefore, these genes have the potential to serve as blood biomarkers for PD 323 vulnerability. Overall, these studies suggest that dysregulation of genes within module M47 involved in 324 blood-oxygen transport and the immune system influence brain regions to be selectively vulnerable to 325
PD. 326
Identification of transcriptomic features in regions or disease conditions may be confounded by changes 327 in cell-type composition. We used PSEA 24 to examine the impact of this confounding factor and found that 328 all 960 BRGs remained differentially expressed between regions R1 and R6 in AHBA. We also applied 329 PSEA in the two PD datasets that allowed us to examine cell-type specificity between regions as well as 330 between disease conditions. Although it is known that gene expression varies more between regions than 331 between disease conditions 22 , it is less clear how cell-type composition contributes to this variation. Here, 332
we found that regional comparisons yielded more significant results than when comparing disease changes were less dependent on cell-type abundance between regions than between patients and 335 controls. 336
In conclusion, we identified genes and pathways that may be important to maintain biological processes 337 in specific brain regions, but may also contribute to a higher selective vulnerability to PD. Our results 338 suggest that interactions between microglial genes and genes involved in dopamine synthesis and motor 339 functions, as well as between genes involved in blood-oxygen transport and the immune system may 340 contribute to the early involvement of specific brain regions in PD progression. Our observations highlight 341 a potential complex interplay of pathways in healthy brains and provide clues for future genetic targets 342 concerning the pathobiology in PD brains. 343
Methods
344
Methods and any associated references are available in the online version of the paper. 345 Table 1 and Supplementary Figure 1) . Through correlation and differential expression analysis, we identified Braak 
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The resulting modules of genes were subsequently analyzed to detect common biologically meaningful pathways. 
Figure 2 Expression patterns of Braak stage-related genes across brain regions of non-neurological, iLBD
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In the PD datasets, SNCA expression was tested for differential expression between 
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To avoid capturing donor-specific changes, we applied the correlation and differential expression 581 analyses for each of the six brain donors separately, and effect sizes were then combined by meta-582 analysis (metafor R-package 2.0). A random effects model was applied which assumes that each brain is 583 considered to be from a larger population of brains and therefore takes the within-brain and between-584 brain variance into account. The between-brain variance (tau 2 ) was estimated with the Dersimonian-585 Delaird model. Variances and confidence intervals were obtained using the escalc-function. Correlations 586
were Fisher-transformed (z = arctanh(r)) to obtain summary estimates, which were then back-transformed 587
to correlation values ranging between -1 and +1. P-values were BH-corrected for all 20,017 genes. The 588 significance of summary effect sizes (correlations and FCs) was assessed through a two-sided t-test (H 0 : 589 FC=0; unequal variances). The weights used in the meta-analysis are based on the non-pooled 590 expression variance in R1-R6. 591 UK Brain Expression Consortium (UKBEC). UKBEC 20 (http://www.braineac.org) contains microarray 592 expression data from 10 brain regions of 134 non-neurological donors (74.5% males, mean age 59, range 593 16-102 years) for which their control status was confirmed by histology. We used the biomaRt R-package 594 version 2.38 44 to map Affymetrix probe IDs from UKBEC to gene Entrez IDs; 262,134 out of 318,197 595 probes could be mapped. Similar as for AHBA, expression data for all probes and samples was 596 concatenated across the 10 brain regions before mapping probes to 18,333 genes with unique Entrez IDs 597 using the collapseRows-function.
